HarryADrabkinMD

Professor of Medicine & Gilbreth Chair in Clinical Oncology Director, Division of Hematology/Oncology Medical University of South Carolina

Join to view full profile

Dr. Drabkin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Drabkin's full profile

Already have an account?

Office
985 S Pearl St
Denver, CO 80209
Is this information wrong?

Education & Training

University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1977 - 1980
University of Kansas School of MedicineClass of 1977

Certifications & Licensure

MT State Medical License 2021 - 2025
CO State Medical License 1980 - 2025
AK State Medical License 2023 - 2024
OH State Medical License 1978 - 2019
SC State Medical License 2007 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

A Phase II Study of AS1411 in Renal Cell Carcinoma Start of enrollment: 2008 Aug 01
Unknown status
Phase 2
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery Start of enrollment: 2008 Oct 01
Terminated
Phase 1
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
Completed
Phase 1
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma Start of enrollment: 2013 Feb 01
Terminated
Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 1
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Docetaxel and Lycopene in Metastatic Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

5 citations
Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Anastasios Dimou, Cecile Nasarre, Yuri K. Peterson, Rose Pagano, Monika Gooz, Patrick Nasarre, Harry A. Drabkin, Kent Armeson, Barry C. Gibney, Robert M. Gemmill, Chad...> ;The Journal of Thoracic and Cardiovascular Surgery. 2021 Aug 1
94 citations
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Bernard Escudier, Thomas Powles, Robert J. Motzer, Thomas Olencki, Osvaldo Arén Frontera, Stéphane Oudard, Frederic Rolland, Piotr Tomczak, Daniel Castellano, Leonard ...> ;Journal of Clinical Oncology. 2018 Jan 8
4 citations
A triad of NRP2, DLX and p53 proteins in lung cancer metastasis.
Harry A. Drabkin, Julia Starkova, Robert M. Gemmill> ;Oncotarget. 2017 Oct 26
3 citations
A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.
Mauricio Burotto, Maureen Edgerly, Margarita Velarde, Sanjeeve Balasubramaniam, Harry A. Drabkin, Juan G. Gormaz, Ciara C. O’Sullivan, Ravi A. Madan, Tito Fojo> ;The Oncologist. 2017 Aug 1
17 citations
Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer.
Joëlle Roche, Robert M. Gemmill, Harry A. Drabkin> ;Cancers. 2017 Jun 24
35 citations
A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.
Sumanta K. Pal, Harry A. Drabkin, James A. Reeves, John D. Hainsworth, Susan E. Hazel, Dario A. Paggiarino, Jon Wojciak, Gary Woodnutt, Rupal S. Bhatt> ;Cancer. 2017 Feb 15
35 citations
The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer
Robert M. Gemmill, Patrick Nasarre, Joyce Nair-Menon, Federico Cappuzzo, Lorenza Landi, Armida D'Incecco, Hidetaka Uramoto, Takeshi Yoshida, Eric B. Haura, Kent Armeso...> ;Science Signaling. 2017 Jan 17
1 citations
Erratum: Roche, J. et al. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers, 2013, 5, 334...
Joëlle Roche, Patrick Nasarre, Robert M. Gemmill, Aleksander Baldys, Julien Pontis, Christopher Korch, Joelle Guilhot, Slimane Ait-Si-Ali, Harry A. Drabkin> ;Cancers. 2016 Dec 15
12 citations
Urothelial carcinoma of donor origin in a kidney transplant patient
Rosa M. Michel Ortega, Daynna J. Wolff, Cynthia A. Schandl, Harry A. Drabkin> ;Journal for Immunotherapy of Cancer. 2016 Oct 18
73 citations
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Takeshi Yoshida, Lanxi Song, Yun Bai, Fumi Kinose, Jiannong Li, Kim C. Ohaegbulam, Teresita Muñoz-Antonia, Xiaotao Qu, Steven A. Eschrich, Hidetaka Uramoto, Fumihiro T...> ;Plos One. 2016 Jan 20
23 citations
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Sumanta K. Pal, Arun Azad, Shailender Bhatia, Harry A. Drabkin, Brian A. Costello, John Sarantopoulos, Ravindran Kanesvaran, Richard C. Lauer, Alexander Starodub, Ralp...> ;Clinical Cancer Research. 2015 Aug 1
4 citations
Nivolumab in renal cell carcinoma
Rosa M. Michel Ortega, Harry A. Drabkin> ;Expert Opinion on Biological Therapy. 2015 Jun 10
816 citations
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theod...> ;Journal of Clinical Oncology. 2015 May 1
13 citations
Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations.
Karolina Skvarova Kramarzova, Karel Fiser, Ester Mejstrikova, Katerina Rejlova, Marketa Zaliova, Maarten Fornerod, Harry A. Drabkin, Marry M. van den Heuvel-Eibrink, J...> ;Journal of Hematology & Oncology. 2014 Dec 24
66 citations
The emerging role of class-3 semaphorins and their neuropilin receptors in oncology
Patrick Nasarre, Robert M. Gemmill, Harry A. Drabkin> ;Oncotargets and Therapy. 2014 Sep 24
16 citations
Analysis of the t(3;8) of hereditary renal cell carcinoma: a palindrome-mediated translocation.
Takema Kato, Colleen P. Franconi, Molly B. Sheridan, April M. Hacker, Hidehito Inagakai, Thomas W. Glover, Martin F. Arlt, Harry A. Drabkin, Robert M. Gemmill, Hiroki ...> ;Cancer Genetics. 2014 Apr 1
246 citations
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Jonathan E. Rosenberg, Richard Martin Bambury, Eliezer M. Van Allen, Harry A. Drabkin, Primo N. Lara, Andrea L. Harzstark, Nikhil Wagle, Robert A. Figlin, Gregory W. S...> ;Investigational New Drugs. 2014 Feb 1
55 citations
Neuropilin-2 Is Upregulated in Lung Cancer Cells during TGF-β1–Induced Epithelial–Mesenchymal Transition
Patrick Nasarre, Robert M. Gemmill, Vincent A. Potiron, Joëlle Roche, Xian Lu, Anna E. Barón, Christopher Korch, Elizabeth Garrett-Mayer, Alessandro Laganà, Philip H. ...> ;Cancer Research. 2013 Dec 1
53 citations
Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells
Joëlle Roche, Patrick Nasarre, Robert M. Gemmill, Aleksander Baldys, Julien Pontis, Christopher Korch, Joelle Guilhot, Slimane Ait-Si-Ali, Harry A. Drabkin> ;Cancers. 2013 Apr 3
27 citations
Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensors.
Swapnajit Chakravarty, Wei Cheng Lai, Yi Zou, Harry A. Drabkin, Robert M. Gemmill, George R. Simon, Steve H. Chin, Ray T. Chen> ;Biosensors & Bioelectronics. 2013 May 15
39 citations
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
Arvind Dasari, Lia Gore, Wells A. Messersmith, Sami Diab, Antonio Jimeno, Colin D. Weekes, Karl D. Lewis, Harry A. Drabkin, Thomas W. Flaig, D. R. Camidge> ;Investigational New Drugs. 2013 Feb 1
Gene Ontology annotations and resources.
Blake JA, Dolan M, Drabkin H, Hill DP, Li N, Sitnikov D, Bridges S, Burgess S, Buza T, McCarthy F, Peddinti D, Pillai L, Carbon S, Dietze H, Ireland A, Lewis SE, Munga...> ;Nucleic Acids Res.. 2013-01-01
43 citations
Cholesterol and the development of clear-cell renal carcinoma.
Harry A. Drabkin, Robert M. Gemmill> ;Current Opinion in Pharmacology. 2012 Dec 1
108 citations
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung can...
Michael Millward, Timothy J. Price, Amanda R. Townsend, Christopher Sweeney, Andrew Spencer, Shawgi Sukumaran, Angie M. Longenecker, Lonnie Lee, Ana Lay, Girish Sharma...> ;Investigational New Drugs. 2012 Dec 1
12 citations
Functional analysis of the NUP98-CCDC28A fusion protein
Arnaud Petit, Christine Ragu, Gwendoline Soler, Chris Ottolenghi, Caroline Schluth, Isabelle Radford-Weiss, Sylvie Schneider-Maunoury, Isabelle Callebaut, Nicole Dastu...> ;Haematologica. 2012 Mar 1
Join now to see all

Grant Support

SEMA3F And ZEB1 In Lung Cancer: Therapy And Target Gene DiscoveryNational Cancer Institute2008–2011
DNA Sequencing &Analysis CoreNational Cancer Institute2006–2010
Quantitative HOX Expression As Prognostic Marker In AMLNational Cancer Institute2004–2006
Molecular-Genetic Analysis Of 3p14 Genomic StabilityNational Cancer Institute1998–2006
Alterations Of E-Cadherin And Proteasome Function In Progression Of Lung CancerNational Cancer Institute2003
Quantitative HOX Expression As Prognostic Marker In AMLNational Cancer Institute2002
Core--Dna Sequencing And AnalysisNational Cancer Institute2001–2002
Core--Dna SequencingNational Cancer Institute1996–2000
Chromosome 3p211 RegionNational Cancer Institute1995–1997
Characterization Of AML1/ETO Genes In T(8;21) Acute Myelogenous LeukemiaEunice Kennedy Shriver National Institute Of Child Health &Human Development1993–1997
Physical MAP And Contigs For Human Chromosome 3National Human Genome Research Institute1991–1996
Characterization Of The Chromosome 3p14 3p21.1 RegionEunice Kennedy Shriver National Institute Of Child Health &Human Development1991–1994
Rearrangement In Human Leukkemia And Physical MappingEunice Kennedy Shriver National Institute Of Child Health &Human Development1988–1992
Construction Of A Physical MAP For Human Chromosome 3National Human Genome Research Institute1990
Characterization Of The Chromosome 3p14-21 RegionEunice Kennedy Shriver National Institute Of Child Health &Human Development1988–1990
Construction Of A Physical MAP For Human Chromosome 3National Institute Of General Medical Sciences1988–1989
Molecular Analysis Of Renal Cell Carcinoma Chromosome 3 DeletionNational Center For Research Resources1988
Molecular Analysis Of The Renal Cell Carcinoma ChromosomeNational Center For Research Resources1987
NCI Clinical Investigator Award ProgramNational Cancer Institute1985–1987